Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02276170 · ClinicalTrials.gov registry record

Pharmacology of Aminophylline for Acute Kidney Injury in Neonates

A clinical trial, sponsored by Stanford University.

Terminated
Registry status
9
Enrollment target

NCT02276170: Clinical Trial study, sponsored by Stanford University.

NCT02276170 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02276170 was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
9 participants
Enrollment target

Study Summary

Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI.

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2014-10
Est. Completion 2018-08
Stanford University

1,744 total trials

Why NCT02276170 stopped before completion

NCT02276170 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT02276170 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02276170 about?

NCT02276170 is a clinical study titled "Pharmacology of Aminophylline for Acute Kidney Injury in Neonates". Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project wil...

What is the current status of trial NCT02276170?

This trial is currently terminated. The enrollment target is 9 participants. The study started on 2014-10. Estimated completion is 2018-08.

Who is sponsoring clinical trial NCT02276170?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02276170, the US trial registry maintained by the National Library of Medicine. NCT02276170 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.